<DOC>
	<DOCNO>NCT01628068</DOCNO>
	<brief_summary>Patients atrial fibrillation require anticoagulation treatment high risk gastrointestinal bleeding . The investigator propose percutaneous stop oral anticoagulation closure leave atrial appendage Amplatzer ® system patient receive anticoagulant therapy atrial fibrillation without associate valvular heart disease , reduce significantly risk stroke minimize risk bleed group patient high risk event . ELIGIBLE trial ( Left atrial appendage Efficacy GastroIntestinal Bleeding closure ) prospective , multicentric randomize ( 2 1 ) trial , compare percutaneous closure atrial appendage leave versus standard treatment oral anticoagulant patient history gastrointestinal bleeding high embolic risk .</brief_summary>
	<brief_title>ELIGIBLE ( Efficacy Left atrIal Appendage Closure After GastroIntestinal BLEeding )</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<criteria>document atrial fibrilation ( paroxysmal permanent ) without significant heart valve disease &gt; 18 year Classic oral anticoagulation ( INR therapeutic level : 23 ) New oral anticoagulant CHA2DS2VASC score ≥ 3 prior digestive bleeding without treatable cause Informed consent . POF contraindication treatment dual antiplatelet therapy ( aspirin + clopidogrel ) Intracardiac thrombus significant carotid disease Cardioversion schedule within 30 day follow implantation AF control FVM &gt; 100 bpm AF secondary surgery ablation thrombosis patient &lt; 40 year chronic renal insufficiency Cr clearance &lt; 30 ml 2 leave appendage sizeappendage inlet &lt; 12.6 mm &gt; 28.5 ( ETE ) depth appendage &lt; 10mm TEE</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Left atrial appendage occlusion</keyword>
	<keyword>gastrointestinal bleeding</keyword>
</DOC>